Business Wire

CA-SHŌ-GROUP

1.6.2022 19:28:10 CEST | Business Wire | Press release

Share
SHŌ Group Launches Restaurant on San Francisco's Salesforce Park and Global NFT-based Membership Club

Today, SHŌ Group (formerly JSSK Group) emerged from stealth mode to reveal the highly anticipated projects the group has been developing since announcing the signing of their first lease in September 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601006053/en/

AN EXPERIENTIAL HOSPITALITY PLATFORM

SHŌ Group is an experiential hospitality platform that builds communities through the creation of one-of-a-kind guest experiences across fine dining, nightlife, and retail food concepts. The team is led by food and technology entrepreneur Josh Sigel, and SHŌ's namesake celebrated chef of Silicon Valley's elite and award-winning Chef, Shotaro ("Sho") Kamio. Kamio's solo venture, Iyasare, which opened on Fourth Street in Berkeley in 2013, has been his most recognized and highly acclaimed project to date. Investors in SHŌ Group include Salesforce, Erica and Jeff Lawson (CEO of Twilio), Craig Ramsey (Founder of Vlocity), Dan Springer (CEO of DocuSign), and Drew Houston (CEO of DropBox). SHŌ Group has also partnered with Carlo Serafini and Ed Lambert from Bay Area-based Bridge Bank for its banking needs.

ICONIC LOCATION

The group's first restaurant project, SHŌ, will introduce a culinary entertainment and nightlife experience never before seen in the Bay Area. SHŌ will be perched atop San Francisco's newest landmark in the heart of the city, the Transbay Joint Powers Authority’s Salesforce Transit Center. The restaurant is located on the Center's roof, a 5.4-acre public urban oasis in the sky called Salesforce Park. To honor and elevate the restaurant's world-class location, SHŌ Group has partnered with the San Francisco studio of lauded international design firm AvroKO, who are behind some of the world’s most iconic restaurants; as well as AvroKO's award-winning sister studio, Brand Bureau, who created the SHŌ brand.

EXPERIENTIAL CUISINE

The culinary experience will be as unique and exciting as the space itself. Chef Sho will offer a Japanese culinary tradition never before introduced in the U.S.: Irori dining, a rustic farmhouse cuisine, which SHŌ plans to center around a 40-square foot fireplace using only charcoal and kindling to produce the fire for cooking fresh, local ingredients. The rooftop Sky Lounge will feature a modern Japanese sushi bar, tapas, and small dishes. At the helm of SHŌ's sushi offering will be Bay Area sushi master and Michelin Star Chef, Masaki Sasaki.

"SHŌ will be the culmination of my culinary creativity inspired by seasonality, simplicity, and surprise. It is a privilege to introduce Irori cooking to the U.S. in a once-in-a-lifetime location," said Kamio. "Cooking by fire the way Japanese farmers and common folk did for centuries yields umami-laden dishes that delight, drive conversation, and restore the sense of community that once abided by the fireplace."

In addition to their restaurant concept, SHŌ Group has also announced SHŌ Market, a Japanese food market that will be located on the ground level of the Salesforce Transit Center. Guests of the market will choose from a selection of freshly made bento boxes featuring the same quality ingredients as SHŌ. Additionally, SHŌ Market will offer grab-and-go fresh salads, street-food inspired dishes, prepackaged treats, curated sakes, and a selection of beautiful handcrafted home goods.

GLOBAL NFT

SHŌ Group will soon be launching an exclusive NFT-based membership club providing its members access to immersive experiences and specialized services across the SHŌ Group platform initially centered around its flagship restaurant, SHŌ. Offered as an NFT, the SHŌ Club membership becomes an asset to members. It is publicly verifiable on the blockchain and can later be sold or transferred on the secondary market. Utilizing NFTs supports the group's mission to create communities that inspire people to discover, grow, support, and connect, providing members with exponential value for many years to come.

SHŌ Club will have three membership tiers, all of which will grant access to a members-only menu and private lounge located on the rooftop level of the restaurant. A dedicated SHŌ Club concierge will be accessible to all members 24-hours a day, 7-days a week, offering priority reservations, a courtesy car for pick up and drop off, and to ensure that every SHŌ experience moment is effortless and memorable. The mid-tier membership will provide additional benefits, including uniquely curated Omakase dinners featuring celebrity guests, mastermind groups, and educational programming. The highest level of membership will grant ownership-like benefits and include a once-in-a-lifetime highly curated trip to Japan that will provide unprecedented access to unique experiences and locations not available to the public. All initial SHŌ Club members will be known as founding members and will hold the only lifetime global access membership. Founding members will have access to all future SHŌ Group venues and experiences.

"SHŌ Group aims to defy expectations and shift perspectives through meaningful moments and interactions that rewrite the rules of hospitality," said Josh Sigel, CEO of SHŌ Group. "We could not be more excited to bring a world-class culinary and much-needed nightlife experience to the Bay Area along with SHŌ Club, one of the first global NFT-based experiential hospitality clubs. San Francisco is just the beginning."

For more information on the SHŌ Group or on obtaining a SHŌ Club membership, visit https://shogroup.com , or follow us on Twitter at @shoclubsf .

ABOUT SHŌ GROUP

SHŌ Group is a global experiential hospitality platform that builds communities through the creation of one-of-a-kind guest experiences across fine dining, nightlife, and retail food concepts. In 2023, the group's first set of experiences will debut in San Francisco, including SHŌ, its namesake Japanese Restaurant set atop San Francisco's iconic landmark, Salesforce Park, SHŌ Market, a Japanese food retail concept, and SHŌ Club, an exclusive NFT-based membership club providing its members access to unique experiences and services across the SHŌ Group platform initially centered around its restaurant, SHŌ.

SHŌ
TJPA’s Salesforce Park: 425 Mission St, San Francisco, CA 94105
Website: shogroup.com | Twitter: @SHOClubSF | Instagram: @SHOClubSF

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye